At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 161 enrolled
Drug / intervention
JNJ-42165279 +1 moredrug
Likely dose
JNJ-42165279 25 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Subjects With Major Depressive Disorder With Anxious Distress
In Brief
A Phase 2 clinical trial evaluating JNJ-42165279 and Placebo for Depressive Disorder and Anxiety. Completed, enrolled 161 participants across 32 sites in 6 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety and tolerability of JNJ-42165279 in participants with major depressive disorder (MDD) with anxiety symptoms who have had inadequate response to treatment with a selective serotonin reuptake inhibitor (SSRI) or serotonergic/noradrenergic reuptake inhibitor (SNRI).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepressive Disorder, Anxiety
CountriesMoldova, Russia, Spain, Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 2015
Enrollment StartOct 2015
Primary CompletionFeb 2019
TodayJul 2026
First PostedJul 15, 2015
Enrollment StartOct 7, 2015
Primary CompletionFeb 4, 2019
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 11.0 years ago
Interventions
JNJ-42165279drug
JNJ-42165279 will be administered orally at a dose of 25 milligrams (mg) tablet once daily for 6 weeks.
Placeboother
Matching Placebo will be administered orally.